FIELD: biotechnology.
SUBSTANCE: invention relates to gene therapy using a vector carrying the genes Nurr1 and Foxa2, and can be used in medicine for preventing or treating Alzheimer's disease caused by accumulation, aggregation or entanglement of tau protein.
EFFECT: invention enables to inhibit phosphorylation, accumulation, aggregation or entanglement of tau protein due to combined introduction and expression of Nurr1 and Foxa2 genes.
3 cl, 11 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TAU MODULATORS AND METHODS AND COMPOSITIONS FOR THEIR DELIVERY | 2017 |
|
RU2789459C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING DEGENERATIVE BRAIN DISEASE COMPRISING GLYCINE TRANSPORTER AS ACTIVE INGREDIENT | 2021 |
|
RU2816256C1 |
| VECTOR BASED ON ADENO-ASSOCIATED VIRUS FOR THERAPEUTIC DELIVERY TO CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2804953C2 |
| ADENO-ASSOCIATED VIRUS VECTOR FOR THERAPEUTIC DELIVERY INTO THE CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2751952C2 |
| METHOD OF PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | 2009 |
|
RU2496502C2 |
| ANTIBODIES, SPECIFIC TO HYPERPHOSPHORYLATED TAU-PROTEIN, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2727911C2 |
| DRUG FOR THE TREATMENT OF METACHROMATIC LEUKODYSTROPHY AND A METHOD FOR ITS TREATMENT | 2021 |
|
RU2769577C1 |
| INTRATHECAL ADMINISTRATION OF VECTORS BASED ON ADENO ASSOCIATED VIRUSES FOR GENE THERAPY | 2016 |
|
RU2775138C2 |
| ANTIBODIES SPECIFIC TO HYPERPHOSPHORYLATED TAU-PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2760875C1 |
| ADENO-ASSOCIATED VIRUS VECTOR | 2015 |
|
RU2743382C2 |
